國家衛生研究院 NHRI:Item 3990099045/11709
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 852935      在线人数 : 467
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11709


    题名: Topoisomerase 2 alpha plays a pivotal role in the tumor biology of advanced thymic neoplasia
    作者: Liu, JM;Hwang, BS;Wang, LS;Huang, MH;Yen, SH;Li, A;Tiu, CM;Whang-Peng, J
    贡献者: National Institute of Cancer Research
    摘要: Background: Thymic carcinogenesis involves stepwise accumulation of genetic aberrations. Early tumors may experience loss at chromosome 6q25. Gains on chromosome 17q occur in about a third of thymic carcinomas, and is probably linked to amplification of the Topoisomerase 2α and Her-2/neu oncogenes. Patients and Methods: A treatment strategy had been developed for the management of stage IV thymic neoplasia since 1991, incorporating maximal surgical resection, combination chemotherapy using the CAP (cyclophosphamide 500mg/m2, adriamycin 50mg/m2, cisplatin0mg/m2) regimen, and radiation therapy potentiated by high dose weekly 5-fluorouracil leucovorin infusion. From 1991-2005, 35 stage IV(a+b) patients have been treated, including 18 females and 17 males, median age of 47years (range: 11 to 84). Histologically, 21 were thymic carcinoma, 13 type B3 and 1 type B2 thymoma. Selected tumor marker studies were performed retrospectively to correlate with chemotherapy responses in 29 patients with available specimen. Results: T2α gene amplification was identified in 4 aggressive thymic tumors, with concurrent amplification of the her2/neu gene in 3 patients. CAP chemotherapy was prescribed for 30 patients, with 3 complete and 18 partial responses, attaining a response rate of 70% (95% CI 52-84%), 37% experience grade 3+4 neutropenia with fever documented in 2 patients, but there were no mortalities. All responding patients over-expressed the T2α protein, whereas 4 non-responders had absence of protein expression (p=0.0002). Thymidylate synthase and ERCC1 expression was not correlated with tumor response to CAP therapy (p=1 and 0.543 respectively). In univariate analysis, factors significantly influencing patient survival included histological type (type B vs type C, p=0.0004), resectability (resectable vs unresectable, p=0.0009), Her2/neu gene amplification (negative vs positive, p=0.0284) Conclusions: Topoisomerase 2α gene amplification and protein over-expression plays a significant role in the tumor biology and therapy of thymic neoplasia. It is especially significant that expression of the topoisomerase 2α protein predicts chemotherapy response to an anthracycline containing regimen, and its absence predicts resistance.
    日期: 2006-04
    關聯: Cancer Research. 2006 Apr;66(8, Suppl.):122-125.
    Link to: http://cancerres.aacrjournals.org/content/66/8_Supplement/125.4
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000454606201188
    显示于类别:[劉敏(1996-2007)] 會議論文/會議摘要
    [彭汪嘉康(1996-2007)] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈